10-Q 1 rviv-20200229_10q.htm FORM 10-Q FOR PERIOD ENDING FEBRUARY 29, 2020
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

☒    QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended February 29, 2020

 

☐    TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

 

Commission File Number: 333-220846

 

Reviv3 Procare Company

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   47-4125218
(State or Other Jurisdiction of
Incorporation or Organization)		   (I.R.S. Employer
Identification No.)
     
9480 Telstar Avenue., Unit 5, El Monte, CA   91731
(Address of Principal Executive Office)   (Zip Code)

 

(888) 638-8883

(Registrant’s Telephone Number, Including Area Code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Not Applicable    

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer           ☐   Accelerated filer ☐
Non-accelerated filer             ☐   Smaller reporting company  ☒
(Do not check if a smaller reporting company)   Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ☒ 

 

As of April 6, 2020, there were 41,285,881 shares of the registrant’s common stock, $0.0001 par value, outstanding.

 
 
 
 

REVIV3 PROCARE COMPANY

INDEX

 

    Page
     
PART I - FINANCIAL INFORMATION  
     
Item 1. Financial Statements 1
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 2
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 7
     
Item 4. Controls and Procedures 7
     
PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 8
     
Item 1A. Risk Factors 8
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 8
     
Item 3. Defaults Upon Senior Securities 8
     
Item 4. Mine Safety Disclosures 8
     
Item 5. Other Information 8
     
Item 6. Exhibits 9
     
Signatures 10

 

 

FORWARD-LOOKING STATEMENTS

 

Except for any historical information contained herein, the matters discussed in this quarterly report on Form 10-Q contain certain “forward-looking statements’’ within the meaning of the federal securities laws. This includes statements regarding our future financial position, economic performance, results of operations, business strategy, budgets, projected costs, plans and objectives of management for future operations, and the information referred to under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

 

These forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,’’ “will,’’ “expect,’’ “intend,’’ “estimate,’’ “anticipate,’’ “believe,’’ “continue’’ or similar terminology, although not all forward-looking statements contain these words. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, you are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although we believe that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Important factors that may cause actual results to differ from projections include, for example:

 

  ● the success or failure of management’s efforts to implement our business plan;
     
  ● our ability to fund our operating expenses;
     
  ● our ability to compete with other companies that have a similar business plan;
     
  ● the effect of changing economic conditions impacting our plan of operation;
     
  ● The scope and duration of the COVID-19 outbreak and its impact on global economic systems; and
     
  ●

our ability to meet the other risks as may be described in future filings with the Securities

and Exchange Commission (the “SEC”).

 

Unless otherwise required by law, we also disclaim any obligation to update our view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this quarterly report on Form 10-Q.

 

When considering these forward-looking statements, you should keep in mind the cautionary statements in this quarterly report on Form 10-Q and in our other filings with the SEC. We cannot assure you that the forward-looking statements in this quarterly report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may prove to be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.

 

 

 

 

PART 1 – FINANCIAL INFORMATION

  

ITEM 1. FINANCIAL STATEMENTS

 

 

REVIV3 PROCARE COMPANY

INDEX TO FINANCIAL STATEMENTS

FEBRUARY 29, 2020

UNAUDITED

 

CONTENTS

 

Condensed Balance Sheets as of February 29, 2020 (Unaudited) and May 31, 2019 F-1
   
Condensed Statements of Operations for the three months and nine months ended February 29, 2020 and February 28, 2019 (Unaudited) F-2
   
Condensed Statements of Changes in Stockholders' Equity for the three months and nine months ended February 29, 2020 and February 28, 2019 (Unaudited) F-3
   
Condensed Statements of Cash Flows for the nine months ended February 29, 2020 and February 28, 2019 (Unaudited) F-4
   
Condensed Notes to Unaudited Financial Statements F-5 - F-14

 

 -1-

 

REVIV3 PROCARE COMPANY

CONDENSED BALANCE SHEETS

 

   February 29, 2020  May 31, 2019
    (Unaudited)      
ASSETS          
 CURRENT ASSETS:          
 Cash  $142,690   $346,179 
 Accounts receivable, net   59,927    79,588 
 Inventory   344,477    264,578 
 Prepaid expenses and other current assets   1,290    2,993 
           
 Total Current Assets   548,384    693,338 
           
 OTHER ASSETS:          
 Intangible assets, net   —      474 
 Property and equipment, net   34,035    32,803 
 Deposit   16,278    14,849 
 Right of use assets, net   219,105    --_ 
           
 Total Other Assets   269,418    48,126 
           
 TOTAL ASSETS  $817,802   $741,464 
           
 LIABILITIES AND STOCKHOLDERS' EQUITY          
           
 CURRENT LIABILITIES:          
 Accounts payable and accrued expenses  $63,714   $32,471 
 Customer deposits   16,203    16,203 
 Due to related party   210    210 
 Equipment financing payable, current   3,300    3,300 
 Lease liability, current   68,941    —   
           
 Total Current Liabilities   152,368    52,184 
           
 LONG TERM LIABILITIES:          
 Equipment financing payable   9,625    11,910 
 Lease liability, non-current   151,021    —   
           
 Total Liabilities   313,014    64,094 
           
 Commitments and contingencies (see Note 9)          
           
 STOCKHOLDERS' EQUITY:          
Preferred stock, $0.0001 par value; 20,000,000 shares authorized; none issued and outstanding   —      —   
Common stock, $0.0001 par value: 100,000,000 shares authorized; 41,285,881 shares issued and outstanding as of February 29, 2020 and May 31, 2019   4,129    4,129 
Additional paid-in capital   5,311,383    5,311,383 
Accumulated deficit   (4,810,724)   (4,638,142)
           
 Total Stockholders' Equity   504,788    677,370 
           
 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $817,802   $741,464 

 

The accompanying notes are an integral part of these condensed unaudited financial statements.

 

F-1

REVIV3 PROCARE COMPANY

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   For the Three Months Ended  For the Nine Months Ended
   February 29,            February 28,  February 29,             February 28,
   2020  2019  2020  2019
             
 Sales  $157,880   $281,062   $612,114   $662,401 
                     
 Cost of sales   45,736    158,846    260,603    382,238 
                     
 Gross profit   112,144    122,216    351,511    280,163 
                     
 OPERATING EXPENSES:                    
 Marketing and selling expenses   37,497    22,439    140,260    63,911 
 Compensation and related taxes   7,624    7,344    38,817    22,430 
 Professional and consulting expenses   43,431    37,732    142,263    157,912 
 General and administrative   64,703    58,212    201,699    190,538 
                     
 Total Operating Expenses   153,255    125,727    523,039    434,791 
                     
 LOSS FROM OPERATIONS   (41,111)   (3,511)   (171,528)   (154,628)
                     
OTHER INCOME (EXPENSE):                    
 Interest income   25    49    95    95 
 Interest expense and other finance charges   (513)   (106)   (1,149)   (378)
                     
Other Income (Expense), Net   (488)   (57)   (1,054)   (283)
                     
 LOSS BEFORE PROVISION FOR INCOME TAXES   (41,599)   (3,568)   (172,582)   (154,911)
                     
 Provision for income taxes   —      —      —      —   
                     
 NET LOSS  $(41,599)  $(3,568)  $(172,582)  $(154,911)
                     
NET LOSS PER COMMON SHARE - Basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.00)
                     
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:                    
 Basic and diluted   41,285,881    41,277,547    41,285,881    40,808,595 

 

The accompanying notes are an integral part of these condensed unaudited financial statements.

 

F-2

REVIV3 PROCARE COMPANY

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

FOR THE THREE MONTHS AND NINE MONTHS ENDED FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

(UNAUDITED)

 

For the three months ended February 29, 2020                
    Preferred Stock   Common Stock   Additional Paid-in   Accumulated   Stockholders'
    Shares   Amount   Shares   Amount   Capital   Deficit   Equity
Balance, November 30, 2019     —       $ —         41,285,881     $ 4,129     $ 5,311,383     $ (4,769,125 )   $ 546,387  
                                                         
Net loss for the three months ended February 29, 2020     —         —         —         —         —         (41,599 )     (41,599 )
                                                         
Balance, February 29, 2020     —       $ —         41,285,881     $ 4,129     $ 5,311,383     $ (4,810,724 )   $ 504,788  
                                                         
For the nine months ended February 29, 2020                                  
      Preferred Stock        Common Stock        Additional Paid-in       Accumulated       Stockholders'  
      Shares       Amount       Shares       Amount       Capital       Deficit       Equity   
Balance, May 31, 2019     —       $ —         41,285,881     $ 4,129     $ 5,311,383     $ (4,638,142 )   $ 677,370  
                                                         
Net loss for the nine months ended February 29, 2020     —         —         —         —         —         (172,582 )     (172,582 )
                                                         
Balance, February 29, 2020     —       $ —         41,285,881     $ 4,129     $ 5,311,383     $ (4,810,724 )   $ 504,788  
                                                         
                                                         
For the three months ended February 28, 2019                                  
      Preferred Stock        Common Stock        Additional Paid-in       Accumulated       Stockholders'  
      Shares       Amount       Shares       Amount       Capital       Deficit       Equity   
Balance, November 30, 2018     —       $ —         41,277,547     $ 4,128     $ 5,306,384     $ (4,639,510 )   $ 671,002  
                                                         
Net loss for the three months ended February 28, 2019     —         —         —         —         —         (3,568 )     (3,568 )
                                                         
Balance, February 28, 2019     —       $ —         41,277,547     $ 4,128     $ 5,306,384     $ (4,643,078 )   $ 667,434  
                                                         
For the nine months ended February 28, 2019                                  
      Preferred Stock        Common Stock        Additional Paid-in       Accumulated       Stockholders'  
      Shares       Amount       Shares       Amount       Capital       Deficit       Equity   
Balance, May 31, 2018     —       $ —         40,505,047     $ 4,051     $ 4,997,461     $ (4,488,167 )   $ 513,345  
                                                         
Issuance of common stock for cash     —         —         760,000       76       303,924       —         304,000  
                                                         
Shares to be issued for services     —         —         12,500       1       4,999       —         5,000  
                                                         
Net loss for the nine months ended February 28, 2019     —         —         —         —         —         (154,911 )     (154,911 )
                                                         
Balance, February 28, 2019     —       $ —         41,277,547     $ 4,128     $ 5,306,384     $ (4,643,078 )   $ 667,434  

 

The accompanying notes are an integral part of these condensed unaudited financial statements.

 

F-3

REVIV3 PROCARE COMPANY

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   For the Nine Months Ended
   February 29, 2020  February 28, 2019
       
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(172,582)  $(154,911)
Adjustments to reconcile net loss to net cash used in operating activities:          
     Depreciation   7,998    3,625 
     Bad debts (recovery)   (2,342)   2,786 
     Stock based compensation   —      5,000 
           
     Intangibles written off   474    —   
Change in operating assets and liabilities:          
Accounts receivable   22,004    (11,316)
Inventory   (79,899)   (106,224)
Advance to suppliers   —      3,413 
Prepaid expenses and other current assets   1,703    3,505 
Deposits   (1,429)   —   
Right of use assets   857    —   
Accounts payable and accrued expenses   31,242    91,508 
           
Customer deposits   —      42,447 
Other liabilities   —      (47)
           
NET CASH USED IN OPERATING ACTIVITIES   (191,974)   (120,214)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (9,230)   (13,887)
           
NET CASH USED IN INVESTING ACTIVITIES   (9,230)   (13,887)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Issuance of common stock for cash   —      304,000 
Repayment of equipment financing   (2,285)   (275)
Advances from a related party   —      3,000 
           
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES   (2,285)   306,725 
           
NET (DECREASE) INCREASE IN CASH   (203,489)   172,624 
           
CASH - Beginning of period   346,179    227,870 
           
CASH - End of period  $142,690   $400,494 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid during the period for:          
   Interest  $1,149   $378 
   Income taxes  $—     $—   
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid during the period for:          
Financing of equipment  $—     $16,500 
Right of use assets recognized as lease liability  $235,748   $—   
Right of use assets amortization  $15,786   $—   

 

The accompanying notes are an integral part of these condensed unaudited financial statements.

 

F-4

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 1 – Organization

 

Reviv3 Procare Company (the “Company”) was incorporated in the State of Delaware on May 21, 2015 as a reorganization of Reviv3 Procare, LLC which was organized on July 31, 2013. The Company is engaged in the manufacturing, marketing, sale and distribution of professional quality hair and skin care products throughout the United States, Canada, Europe and Asia.

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies

 

Basis of Presentation

 

The unaudited financial statements for the three and nine months ended February 29, 2020 and February 28, 2019 have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of the management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of February 29, 2020 and February 28, 2018, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been omitted. The unaudited financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended May 31, 2019. The results of operations for the three months and nine months ended February 29, 2020 are not necessarily indicative of the results to be expected for the full year.

 

Going Concern

 

As reflected in the accompanying financial statements, the Company has a net loss of $172,582 for the nine months ended February 29, 2020, and used cash from operating activities of $191,974 for the nine months ended February 29, 2020.  Additionally, the Company has an accumulated deficit of $4,810,724 at February 29, 2020. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this report. The ability of the Company to continue as a going concern is dependent on the Company’s ability to continue its business plan, raise capital, and generate sufficient revenue; however, the Company’s cash position may not be sufficient to support its daily operations. While the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Use of estimates

 

The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations, the useful life of property and equipment, the valuation of intangible assets, the valuation of deferred tax assets, the value of stock-based compensation, and the fair value of non-cash common stock issuances. 

 

Cash and cash equivalents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents.  The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.

 

F-5

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Accounts receivable and allowance for doubtful accounts

 

The Company has a policy of providing on allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.  The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.  Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

Prepaid expenses and other current assets

 

Prepaid expenses and other current assets of $1,290 and $2,993 at February 29, 2020 and May 31, 2019, respectively, consist primarily of costs paid for future services which will occur within a year and cash prepayment to vendors. Prepaid expenses at February 29, 2020 and May 31, 2019 primarily included cash prepayment to vendors.   

 

 Inventory

 

The Company values inventory, consisting of finished goods and raw materials, at the lower of cost and net realizable value. Cost is determined using an average cost method. The Company reduces inventory for the diminution of value, resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its net realizable value. The Company evaluates its current level of inventory considering historical sales and other factors and, based on this evaluation, classifies inventory markdowns in the statement of operations as a component of cost of goods sold. These markdowns are estimates, which could vary significantly from actual requirements if future economic conditions, customer demand or competition differ from expectations.

  

Property and Equipment

 

Property and equipment are carried at cost less accumulated depreciation.  Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized.  When assets are retired or disposed of, the cost and accumulated depreciation are removed, and any resulting gains or losses are included in the statement of operations.

 

Revenue recognition

 

Effective June 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) 606, “Revenue From Contracts With Customers”, which is effective for public business entities with annual reporting periods beginning after December 15, 2017.  This new revenue recognition standard (new guidance) has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied. The impact of the Company’s initial application of ASC 606 did not have a material impact on its financial statements and disclosures and there was no cumulative effect of the adoption of ASC 606.

 

The Company sells a variety of hair and skin care products. The Company recognizes revenue for the agreed upon sales price when a purchase order is received from the customer and subsequently the product is shipped to the customer, which satisfies the performance obligation. Consideration paid to the customer to promote and sell the Company’s products is typically recorded as a reduction in revenues. See Note 11 for revenue disaggregation disclosures.

 

Cost of Sales

 

The primary components of cost of sales include the cost of the product and freight-in.

 

F-6

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Shipping and Handling Costs

 

The Company accounts for shipping and handling fees in accordance with ASC 606. While amounts charged to customers for shipping products are included in revenues, the related costs of shipping products to customers are classified in marketing and selling expenses as incurred. Shipping costs included in marketing and selling expense were $11,292 and $11,900 for the three months ended February 29, 2020 and February 28, 2019, respectively. Shipping costs included in marketing and selling expense were $31,898 and $30,601 for the nine months ended February 29, 2020 and February 28, 2019, respectively.

 

Marketing, selling and advertising

 

Marketing, selling and advertising costs are expensed as incurred.

 

Customer Deposits

 

Customer deposits consisted of prepayments from customers to the Company. The Company will recognize the prepayments as revenue upon delivery of products in compliance with its revenue recognition policy.

 

Fair value measurements and fair value of financial instruments

 

The Company adopted ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: 

 

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:

Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s

own assumptions.

 

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

The estimated fair value of certain financial instruments, including prepaid expenses, deposits, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

F-7

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

The Company follows the provision of ASC 740-10 related to “Accounting for Uncertain Income Tax Positions”. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open.  The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.

  

Impairment of long-lived assets  

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company recorded impairment losses of $474 as an operating expense in the accompanying financial statements, during the nine months ended February 29, 2020.

 

Stock-based compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

Pursuant to ASC Topic 505-50, “Equity Based Payments to Non-employees”, for share-based payments to consultants and other third-parties, compensation expense is determined at the measurement date. The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. 

 

Net loss per share of common stock

 

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period. At February 29, 2020 and February 28, 2019, the Company had no potentially dilutive securities outstanding.

 

F-8

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

Accounting Changes

In February 2016, the FASB issued ASU No. 2016-02, “Leases”, which require lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance. Under the new guidance, codified as ASC Topic 842, Leases, the lease liability must be measured initially based on the present value of future lease payments, subject to certain conditions. The right-of-use asset must be measured initially based on the amount of the liability, plus certain initial direct costs. As permitted, the Company adopted ASC Topic 842 effective May 1, 2019 using the optional cumulative-effect transition method. The Company, signed a lease for 3 years on December 1, 2019 and will record the initial lease liability and right-of-use asset, in the same aggregate amount. The Company’s right-of-use asset relates to the lease involving office space and will be amortized over the lease term of three years. The adoption of ASC Topic 842 did not otherwise have a material impact on the Company’s financial statements.

 

Recently Issued Accounting Pronouncements

 

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement” (Topic 820) which modifies the disclosure requirements on fair value measurements under ASC Topic No. 820, Fair Value Measurement, as amended (“ASC 820”). For public companies, ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 of the fair value hierarchy (please see Note 3 below for discussion of the three-level hierarchy for measuring fair value), (b) the policy for timing of transfers between levels, and (c) the valuation processes used for level 3 fair value measurements. For public companies, ASU 2018-13 also adds, among other things, a requirement to disclose the range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. This amendment is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption was permitted upon issuance of ASU 2018-13. The Company has not adopted ASU 2018-13 and, based on its preliminary assessment, does not believe the impact of adoption will be material on its financial statements.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 

F-9

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 3 – Accounts Receivable

 

Accounts receivable, consisted of the following:

 

   February 29, 2020  May 31, 2019
Accounts Receivable  $60,362   $82,365 
Less: Allowance for doubtful debts   (435)   (2,777)
   $59,927   $79,588 

  

The Company recorded bad debt recovery of ($2,342) and bad debt expense of $2,786 during the nine months ended February 29, 2020 and February 28, 2019, respectively.

 

Note 4 – Inventory

 

Inventory consisted of the following:

 

   February 29, 2020  May 31, 2019
Finished Goods  $40,671   $69,256 
Raw Materials   303,806    195,322 
   $344,477   $264,578 

 

At February 29, 2020 and May 31, 2019, inventory held at third party locations amounted to $580 and $13,176, respectively. At February 29, 2020 and May 31, 2019, inventory in- transit amounted to $0 and $3,450, respectively.

 

During the nine months ended February 29, 2020 the Company sold some of the slow- moving inventory which had been written off and recovered $769. During the nine months ended February 28, 2019, the Company wrote down inventory for obsolescence of $636 which is included in cost of sales.

 

Note 5 – Property and Equipment

 

Property and equipment, stated at cost, consisted of the following:

 

   Estimated Life  February 29, 2020  May 31, 2019
Furniture and Fixtures  5 years  $5,759   $5,759 
Computer Equipment  3 years   17,392    17,392 
Plant Equipment  5-10 years   29,720    20,490 
Less: Accumulated Depreciation      (18,836)   (10,838)
      $34,035   $32,803 

 

Depreciation expense amounted to $2,459 and $1,582 for the three months ended February 29, 2020 and February 28, 2019, respectively. Depreciation expense amounted to $7,998 and $3,625 for the nine months ended February 29, 2020 and February 28, 2019, respectively.

 

F-10

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 6 – Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses comprised of the following:

 

   February 29, 2020  May 31, 2019
Trade Payables  $48,173   $14,610 
Credit Cards   12,905    14,407 
Other   2,636    3,454 
   $63,714   $32,471 

 

Note 7 – Equipment Financing Payable

 

During the year ended May 31, 2019, the Company purchased a forklift under an installment purchase plan. The loan amount was $16,500 payable in 60 monthly installment payments of $317 comprising of principal payment of $275 and interest payment of $42. As of February 29, 2020, and May 31, 2019, the balance outstanding on the loan was $12,925 and $15,210. $3,300 of the loan is payable within one year and the balance $9,625, is payable after one year from February 29, 2020. The Company recorded an interest expense of $31 and $10, respectively on the loan in the accompanying unaudited financial statements for the three months and nine months ended February 29, 2020. The Company recorded an interest expense of $42 on the loan in the accompanying unaudited financial statements for the three months and nine months ended February 28, 2019.

 

The amounts of principal payments due in the next five years ended February 28, are as follows:

 

  2021   $ 3,300  
  2022     3,300  
  2023     3,300  
  2024     3,025  
      $ 12,925  

 

Note 8 – Stockholders’ Equity

 

Shares Authorized

 

The authorized capital of the Company consists of 100,000,000 shares of common stock, par value $0.0001 per share and 20,000,000 shares of preferred stock, par value $0.0001 per share.

 

Preferred Stock

 

The preferred stock may be issued from time to time in one or more series. The Board of Directors of the Company is expressly authorized to provide for the issuance of all or any of the shares of the preferred stock in one or more series, and to fix the number of shares and to determine or alter, for each such series, such voting powers, full or limited, or no voting powers and such designations, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed until the resolution adopted by the Board of Directors providing the issuance of such shares. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issue of shares of that series. In case the number of shares of any such series shall be so decreased, the decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.

 

As of February 29, 2020, no shares of preferred stock were issued and outstanding.

 

F-11

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 8 – Stockholders’ Equity (continued)

 

Common Stock

 

As of February 29, 2020, 41,285,891 shares of common stock were issued and outstanding. 

 

No stock was issued during the nine months ended February 29, 2020.

 

During the nine months period ended February 28, 2019, the Company issued 760,000 shares of common stock for $304,000 cash proceeds to third party investors at $0.40 per share.

 

During the nine months period ended February 28, 2019, the Company recorded 12,500 shares of common stock for shares earned by third party consultant for services provided to the Company. The shares were valued at $0.40 per share or $5,000, based on the recent common stock sales.

 

Note 9 – Commitments and Contingencies

 

Leases

 

As discussed in Note 2 above, the Company adopted ASU No. 2016-02, “Leases” on June 1, 2019, which require lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance. The Company has a lease agreement in connection with its office and warehouse facility in California under an operating lease which expired in October 2019. On December 1, 2019, the Company signed an extension of the lease for 3 years. The rent will be $7,567.34 per month for the first year and increase by a certain amount each year.

 

The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period of time in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.

 

The Company reviews the impairment of ROU assets consistent with the approach applied for the Company’s other long-lived assets. The Company reviews the recoverability of long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations.

 

Lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. Variable payments change due to facts or circumstances occurring after the commencement date, other than the passage of time, and do not result in a remeasurement of lease liabilities. The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants.

 

F-12

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 9 – Commitments and Contingencies (continued)

 

Pursuant to the new standard, the Company recorded an initial lease liability of $235,748 and an initial right of use asset in the same amount. During the three months ended February 29, 2020, the Company recorded rent expense in the amount of $23,589 for the three months ended February 29, 2020. As of February 29, 2020, the lease liability balance was $219,962 and the right of use asset balance was $219,105. A lease term of three years and a discount rate of 12% was used.

 

Supplemental balance sheet information related to leases was as follows:

 

   February 29, 2020
Assets     
Operating lease assets, net  $213,452 
      
Liabilities     
Current Operating   68,941 
Non-current Operating   151,021 
Total Lease Liabilities  $219,962 

 

Maturities of operating lease liabilities were as follows as of February 29, 2020:

 

Operating Lease   
Year 1  $91,665 
Year 2   95,091 
Year 3   73,246 
Total   260,002 
Less: Imputed interest   (40,040)
Present value of lease liabilities   219,962 
Less: current portion   (68,941)
Non- current portion  $151,021 

 

Rent expense, prior to the signing of the new lease agreement, amounted to $0 and $23,666 for the three months ended February 29, 2020 and February 28, 2019, respectively. Rent expense amounted to $71,105 and $71,203 for the nine months ended February 29, 2020 and February 28, 2019, respectively.

 

Note 10 – Related Party Transactions

 

The Company’s Chief Executive Officer, from time to time, provided advances to the Company for working capital purposes. At February 29, 2020 and May 31, 2019, the Company had a payable to the officer of $210 and $210, respectively. These advances are unsecured, due on demand and non-interest bearing.

 

During the nine months ended February 28, 2019, the Company paid $280 to an affiliated company for advisory services rendered. The affiliated company is managed by the Company’s Chief Executive Officer.

 

F-13

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 29, 2020 AND FEBRUARY 28, 2019

 

Note 11 – Concentrations and Revenue Disaggregation

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade accounts receivable and cash deposits, investments and cash equivalents instruments. The Company maintains its cash in bank deposits accounts. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At February 29, 2020 and May 31, 2019, the Company held cash of approximately $0 and $102,454, respectively, in excess of federally insured limits. The Company has not experienced any losses in such accounts through February 29, 2020.

 

Concentration of Revenue, Product Line, Accounts Receivable and Supplier

 

During the three months ended February 29, 2020 sales to four customers, which each represented over 10% of our total sales, aggregated to approximately 68% of the Company’s net sales at 21%, 20%, 15% and 12%. During the nine months ended February 29, 2020, sales to three customers, which each represented over 10% of our total sales, aggregated to approximately 48% of the Company’s net sales at 26%, 10% and 12%. During the three months ended February 28, 2019 sales to one customer, which represented over 10% of our total sales, amounted to approximately 50% of the Company’s net sales. During the nine months ended February 28, 2019 sales to two customers, which each represented over 10% of our total sales, aggregated to approximately 51% of the Company’s net sales at 38% and 13%.

 

During the three months ended February 29, 2020, sales to customers outside the United States represented approximately 42% which consisted of 41% from Canada and 1% from other countries and during the nine months ended February 29, 2020, sales to customers outside the United States represented approximately 33% which consisted of 24% from Canada, 8% from Italy and 1% from UK. During the nine months period ended February 28, 2019 sales to customers outside the United States represented approximately 30% which consisted of 20% from Canada, 5% from Italy, 3% from Hong Kong and 2% from United Kingdom. During the three months period ended February 28, 2019 sales to customers outside the United States represented approximately 26% which consisted of 22% from Canada and 4% from United Kingdom.

 

During the nine months ended February 29, 2020, sales by product lines which each represented over 10% of sales consisted of approximately 17% from sale of introductory kit (shampoo, conditioner and treatment spray) and 26% from sale of fragrance shampoo and conditioner. During the three months ended February 29, 2020, sales by product lines which each represented over 10% of sales consisted of approximately 25% from sale of introductory kit (shampoo, conditioner and treatment spray), 26% from sale of prep shampoo and 10% from prime moisturizer and conditioner. During the nine months period ended February 28, 2019, sales by product line which each represented over 10% of sales consisted of approximately 20% from sale of introductory kit (shampoo, conditioner and treatment spray), 16% from prep shampoo and conditioner, 11% from sale of moisturizer and conditioner and 29% from fragrance shampoo and conditioner. During the three months period ended February 28, 2019, sales by product line which each represented over 10% of sales consisted of approximately 15% from sale of introductory kit (shampoo, conditioner and treatment spray), 21% from fragrance shampoo and 21% from fragrance conditioner. 

 

During the nine months ended February 29, 2020 and February 28, 2019, sales by product line comprised of the following:

 

   For the Nine Months ended
Hair Care Products  February 29, 2020  February 28, 2019
Shampoos and Conditioners   80%   76%
Ancillary Products   20%   24%
Total   100%   100%

 

As of February 29, 2020, accounts receivable from five customers represented approximately 85% at 14%, 15%, 16%, 18% and 22% and at May 31, 2019, accounts receivable from five customers represented approximately 94% at 30%, 13%, 23%, 14% and 14%, respectively.

 

The Company purchased inventories and products from one vendor totaling approximately $203,916 (77% of the purchases) and three vendors totaling approximately $308,761 (76% of the purchases at 10%, 28% and 38%) for the nine months ended February 29, 2020 and February 28, 2019, respectively.

 

F-14

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with, and is qualified in its entirety by, the condensed financial statements and notes thereto included in Item 1 in this Quarterly Report on Form 10-Q. 

 

Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking.  Forward-looking statements are, by their very nature, uncertain and risky.  Forward-looking statements are often identified by words like: “believe”, “expect”, “estimate”, “anticipate”, “intend”, “project” and similar expressions, or words that, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. These risks and uncertainties include international, national, and local general economic and market conditions; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; change in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; the risk of foreign currency exchange rate; and other risks that might be detailed from time to time in our filing with the Securities and Exchange Commission. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q.

 

Although the forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in herein and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

 

Prospective investors should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.”

 

Overview

 

Reviv3 Procare Company is engaged in the manufacturing, marketing, sale and distribution of professional quality hair and skin care products under various trademarks and brands. We have adopted and used the trademarks of our products for distribution throughout the United States, Canada, Europe, and Asia pursuant to the terms of twelve exclusive distribution agreements with various parties throughout our targeted market. Our manufacturing operations are outsourced and fulfilled by our co-packers and manufacturing partners. Currently, we produce seven products with sixteen separate stock-keeping units (“SKUs”) and look to expand our product lines over the next twelve months.

 

-2-

JOBS Act

 

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

 

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions from, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (a) the last day of our fiscal year following the fifth anniversary of the closing of this offering, (b) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (c) the last day of our fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, or Exchange Act (which would occur if the market value of our equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter), or (d) the date on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period.

 

Results of Operations

 

For the Three months and Nine months ended February 29, 2020 Compared to the Three Months and Nine Months ended February 28, 2019

 

Revenues for the three months ended February 29, 2020 and February 28, 2019 were $157,880 and $281,062, respectively. Revenues for the three months ended February 29, 2020 decreased by $123,182 or 44% over the same comparable period in 2019. Revenues for the nine months periods ended February 29, 2020 and February 28, 2019 were $612,114 and $662,401, respectively. Revenues for the nine months ended February 29, 2020 decreased by $50,287 or 8% over the same comparable period in 2019. Revenues have decreased in the 2020 respective periods primarily due to the Company’s inability to receive certain components from China due to extended factory delays caused by Coronavirus (COVID – 19) after the Chinese New Year, and continued diversification of selling our products from domestic distribution to direct to consumer sales channels.

 

Cost of sales consisted primarily of cost of product and freight-in costs. Cost of sales for the three months ended February 29, 2020 and February 28, 2019 was $45,736 and $158,846, respectively. Cost of sales as a percentage of sales for the three months ended February 29, 2020 and February 28, 2019 was 29% and 57%, respectively. Cost of sales for the nine months ended February 29, 2020 and February 28, 2019 was $260,603 and $382,238, respectively. Cost of sales as a percentage of sales for the nine months ended February 29, 2020 and February 28, 2019 was 43% and 58%, respectively. Cost of sales as a percentage of sales decreased in 2020 for the respective periods as compared to the same comparable periods in 2019 primarily due to the Company continued streamlining of its operations for assembly of our products resulting in lower cost of sales.

 

-3-

Gross profit for the three months ended February 29, 2020 and February 28, 2019 was $112,144 and $122,216, respectively. Gross profit as a percentage of revenues for the three months ended February 29, 2020 was 71% as compared to 43% for the same comparable period in 2019. Gross profit for the nine months ended February 29, 2020 and February 28, 2019 was $351,511 and $280,163, respectively. Gross profit as a percentage of revenues for the nine months ended February 29, 2020 was 57% as compared to 42% for the same comparable period in 2019. The increase in gross profit for the nine months ended February 29, 2020 was primarily attributable to the continued refocusing and diversification of our sales channels from the traditional distribution sales to direct to consumer channels.

 

Operating expenses consisted of marketing and selling expenses, professional and consulting fees, compensation to employees and other general and administrative expenses. Operating expenses for the three months ended February 29, 2020 and February 28, 2019 were $153,255 and $125,727, respectively. Operating expenses as a percentage of revenues for the three months ended February 29, 2020 and February 28, 2019 were 97% and 45%, respectively. Operating expenses for the three months ended February 29, 2020 increased by $27,528 or 22% over the comparable period in 2019. Operating expenses for the nine months ended February 29, 2020 and February 28, 2019 were $523,039 and $434,791, respectively. Operating expenses as a percentage of revenues for the nine months ended February 29, 2020 and February 28, 2019 were 85% and 66%, respectively. Operating expenses for the nine months ended February 29, 2020 increased by $88,248 or 20% over the comparable period in 2019. The increase in operating expenses is attributable primarily due to the increase in marketing and advertising expense to promote Company’s brand name and its products in the direct to consumer channels, a general increase in the general and administrative expenses relating to rent, insurance, and other expenses, offset by reduction in independent contractors and their fees and reduction in legal and professional fees during the respective periods in 2020 compared to the same comparable periods in 2019.

 

As a result of the above, we reported a net loss of $41,599 and $172,582 for the three months and nine months ended February 29, 2020 as compared to a net loss of $3,568 and $154,911 for the three months and nine months ended February 28, 2019.

 

Liquidity and Capital Resources

   

We are an emerging growth company and currently engaged in our initial product sales and development. We have an accumulated deficit and have incurred operating losses since our inception and expect losses to continue during the fiscal year 2019. This raises substantial doubt about our ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Cash Flows

 

Operating Activities

 

Net cash flows used in operating activities for the nine months ended February 29, 2020 was $191,974, attributable to a net loss of $172,582, depreciation of $7,998, bad debts recovery of $2,342, write-off of intangibles of $474, and net change in operating assets and liabilities of $25,523 primarily due to decrease in accounts receivable, prepaid expenses and other current assets, and security deposits offset by an increase in inventory, accounts payable and accrued expenses, and right of use assets. Net cash flows used in operating activities for the nine months ended February 28, 2019 was $120,214, attributable to a net loss of $154,911, depreciation of $3,625, bad debt write-off of $2,786, stock based compensation of $5,000 and net change in operating assets and liabilities of $23,286 primarily due to increase in accounts receivable, inventory, advance to suppliers, accounts payable and accrued expenses, customer deposits and other liabilities, and decrease in prepaid expenses and other current assets.

 

-4-

Investing Activities

 

Net cash flows used by investing activities for the nine months ended February 29, 2020 and February 28, 2019 was $9,230 and $13,887, respectively. We purchased property and equipment of $9,230 and $13,887 during the nine months ended February 29, 2020 and February 28, 2019, respectively.

 

Financing Activities

 

Net cash flows used in financing activities for the nine months ended February 29, 2020 was $2,285, and net cash flows provided by financing activities for the nine months ended February 28, 2019 was $306,725, respectively. For the nine months ended February 29, 2020, we paid $2,285 towards equipment financing. For the nine months ended February 28, 2019, we raised $304,000 in capital funds through private placement offerings, received advances from a related party of $3,000, and repaid $275 of the financed equipment.

 

As a result of the activities described above, we recorded a net decrease in cash of $203,489 for the nine months ended February 29, 2020, and a net increase of cash of $172,624 for the nine months ended February 28, 2019.

 

We currently have no external sources of liquidity, such as arrangements with credit institutions or off-balance sheet arrangements that will have or are reasonably likely to have a current or future effect on our financial condition or immediate access to capital.

 

We are dependent on our product sales to fund our operations and may require the sale of additional common stock to expand our operations. Our officers and directors have made no written commitments with respect to providing a source of liquidity in the form of cash advances, loans, and/or financial guarantees.

 

If we are unable to raise the funds required to fund our operations, we will seek alternative financing through other means, such as borrowings from institutions or private individuals. There can be no assurance that we will be able to raise the capital we need for our operations from the sale of our securities. We have not located any sources for these funds and may not be able to do so in the future. We expect that we will seek additional financing in the future. However, we may not be able to obtain additional capital or generate sufficient revenues to fund our operations. If we are unsuccessful at raising sufficient funds, for whatever reason, to fund our operations, we may be forced to cease operations. If we fail to raise funds, we expect that we will be required to seek protection from creditors under applicable bankruptcy laws.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Critical Accounting Policies 

 

The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of expenses during the reporting period. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

 

-5-

We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting policies relate to revenue recognition, impairment of intangible assets and long-lived assets, inventory, stock compensation, and evaluation of contingencies. We believe estimates and assumptions related to these critical accounting policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial condition or results of operations.

 

Significant Accounting Policies

 

See the footnotes to our unaudited condensed financial statements for the quarter ended February 29, 2020, included with this quarterly report.

 

Impact of COVID-19

 

During the three months ended February 29, 2020, the effects of a new coronavirus (“COVID-19”) and related actions to attempt to control its spread began to impact our business. The impact of COVID-19 on our operating results for the three months ended February 29, 2020 was limited, in all material respects, to our sales in Europe and in China where the Chinese government mandated numerous measures, including closures of businesses, limitations on movements of individuals and goods, and the imposition of other restrictive measures, in its efforts to mitigate the spread of COVID-19 within the country.

 

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Governments around the world have mandated, and continue to introduce, orders to slow the transmission of the virus, including but not limited to shelter-in-place orders, quarantines, significant restrictions on travel, as well as work restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic effects of the pandemic has introduced significant volatility in the financial markets.

 

To the extent that COVID-19 continues or worsens, governments may impose additional restrictions or additional governments may impose restrictions. The result of COVID-19 and those restrictions could result in a number of adverse impacts to our business, including but not limited to additional disruption to the economy and consumers’ willingness and ability to spend, temporary or permanent closures by businesses that consume our products, such as salons and spas, additional work restrictions, and supply chains being interrupted, slowed, or rendered inoperable. As a result, it may be challenging to obtain and process raw materials and supply chains to support our business needs, and individuals could become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. Also, governments may impose other laws, regulations or taxes which could adversely impact our business, financial condition or results of operations. Further, if our customers’ businesses or incomes are similarly affected, they might delay or reduce purchases from us. The potential effects of COVID-19 also could impact us in a number of other ways including, but not limited to, reductions to our profitability, laws and regulations affecting our business, the availability of future borrowings, the cost of borrowings, and credit risks of our customers and counterparties.

 

Given the evolving health, economic, social, and governmental environments, the potential impact that COVID-19 could have on our business remains uncertain.

 

-6-

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain "disclosure controls and procedures,” as that term is defined in Rule 13a-15(e), promulgated by the SEC pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of February 29, 2020, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting.

 

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses in our internal control over financial reporting which we identified and previously reported in the Annual Report on Form 10-K for the year ended May 31, 2019: (1) insufficient number of qualified accounting personnel governing the financial close and reporting process, (2) lack of independent directors, and (3) lack of proper segregation of duties.

 

We expect to be materially dependent upon third parties to provide us with accounting and consulting services for the foreseeable future. We believe this will be sufficient to remediate the material weaknesses related to our accounting discussed above. We plan to recruit independent directors in the near future to oversee, establish and maintain adequate internal controls over financial reporting. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures will not result in errors in our financial statements which could lead to a restatement of those financial statements. A material weakness is a deficiency or a combination of control deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

Changes in internal control over financial reporting

 

There were no changes in our internal control over financial reporting during the quarter ended February 29, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

-7-

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not a party to any material litigation, nor, to the knowledge of management, is any litigation threatened against us that may materially affect us.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company, we are not required to provide risk factors. Please refer to our registration statement under Form S-1 for more information regarding risks related to the securities of the Company.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

(a) Not applicable.

 

(b) During the quarter ended February 29, 2020, there have not been any material changes to the procedures by which security holders may recommend nominees to the Board of Directors.

 

-8-

ITEM 6. EXHIBITS

 

            Incorporated by reference
Exhibit       Filed        Period       Filing
Number   Exhibit Description   herewith   Form   Ending   Exhibit   date
31.1   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   X       02/29/2020        
31.2   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   X       02/29/2020        
32.1   Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.   X       02/29/2020        
32.2   Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.   X       02/29/2020        
101.INS   XBRL Instance   X       02/29/2020        
101.SCH   XBRL Taxonomy Extension Schema   X       02/29/2020        
101.CAL   XBRL Taxonomy Extension Calculation   X       02/29/2020        
101.DEF   XBRL Taxonomy Extension Definition   X       02/29/2020        
101.LAB   XBRL Taxonomy Extension Labels   X       02/29/2020        
101.PRE   XBRL Taxonomy Extension Presentation   X       02/29/2020        

 

-9-

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

REVIV3 PROCARE COMPANY

 

 

Date: April 6, 2020

By: /s/ Jeff Toghraie

____________________________

Jeff Toghraie

Chief Executive Officer

(Principal Executive Officer)

 

-10-